– REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder
– Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO
ROCKVILLE, MD and NOVATO, CA, USA I March 31, 2020 I REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies’ existing gene therapy partnership.
Under the terms of the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to REGENXBIO’s NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. In return for these rights, REGENXBIO will receive an upfront payment of $7 million, ongoing fees, milestone payments, and royalties on net sales of products incorporating the licensed intellectual property.
“We are pleased to expand our long-standing relationship with Ultragenyx through this new license agreement, which will enable Ultragenyx to apply our proprietary NAV Vectors to the development of a new gene therapy for rare diseases,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “Today’s announcement provides further validation of the breadth and depth of our intellectual property portfolio, and we remain committed to working closely with leading companies to enable the development of important gene therapy programs.”
“This latest license agreement reinforces Ultragenyx’s commitment to developing gene therapies for multiple rare diseases and adds a new indication to our relationship with REGENXBIO,” said Emil D. Kakkis, MD, PhD, Chief Executive Officer and President of Ultragenyx.
Ultragenyx is a longstanding licensee partner of REGENXBIO. In addition to today’s agreement, Ultragenyx has in-licensed NAV Vectors for the development of gene therapies to treat Ornithine Transcarbamylase (OTC) Deficiency, Glycogen Storage Disease Type Ia (GSDIa), CDKL5 Deficiency, Hemophilia A, and Wilson Disease.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company’s website at www.ultragenyx.com.
SOURCE: REGENXBIO
Post Views: 54
– REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder
– Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO
ROCKVILLE, MD and NOVATO, CA, USA I March 31, 2020 I REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies’ existing gene therapy partnership.
Under the terms of the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to REGENXBIO’s NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. In return for these rights, REGENXBIO will receive an upfront payment of $7 million, ongoing fees, milestone payments, and royalties on net sales of products incorporating the licensed intellectual property.
“We are pleased to expand our long-standing relationship with Ultragenyx through this new license agreement, which will enable Ultragenyx to apply our proprietary NAV Vectors to the development of a new gene therapy for rare diseases,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “Today’s announcement provides further validation of the breadth and depth of our intellectual property portfolio, and we remain committed to working closely with leading companies to enable the development of important gene therapy programs.”
“This latest license agreement reinforces Ultragenyx’s commitment to developing gene therapies for multiple rare diseases and adds a new indication to our relationship with REGENXBIO,” said Emil D. Kakkis, MD, PhD, Chief Executive Officer and President of Ultragenyx.
Ultragenyx is a longstanding licensee partner of REGENXBIO. In addition to today’s agreement, Ultragenyx has in-licensed NAV Vectors for the development of gene therapies to treat Ornithine Transcarbamylase (OTC) Deficiency, Glycogen Storage Disease Type Ia (GSDIa), CDKL5 Deficiency, Hemophilia A, and Wilson Disease.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company’s website at www.ultragenyx.com.
SOURCE: REGENXBIO
Post Views: 54
